Literature DB >> 11113228

Oxidative stress in patients with Friedreich ataxia.

J B Schulz1, T Dehmer, L Schöls, H Mende, C Hardt, M Vorgerd, K Bürk, W Matson, J Dichgans, M F Beal, M B Bogdanov.   

Abstract

Increased generation of reactive oxygen species may underlie the pathophysiology of Friedreich ataxia (FRDA). The authors measured concentrations of 8-hydroxy-2'-deoxyguanosine (8OH2'dG), a marker of oxidative DNA damage, in urine and of dihydroxybenzoic acid (DHBA), a marker of hydroxyl radical attack, in plasma of 33 patients with FRDA. They found a 2.6-fold increase in normalized urinary 8OH2'dG but no change in plasma DHBA as compared with controls. Oral treatment with 5 mg/kg/day of the antioxidant idebenone for 8 weeks significantly decreased urinary 8OH2'dG concentrations, indicating that 8OH2'dG may be useful in monitoring therapeutic interventions in patients with FRDA.-1721

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113228     DOI: 10.1212/wnl.55.11.1719

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  99 in total

1.  Antioxidant enzymes in blood of patients with Friedreich's ataxia.

Authors:  G Tozzi; M Nuccetelli; M Lo Bello; S Bernardini; L Bellincampi; S Ballerini; L M Gaeta; C Casali; A Pastore; G Federici; E Bertini; F Piemonte
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

Review 2.  Friedreich ataxia-update on pathogenesis and possible therapies.

Authors:  Max Voncken; Panos Ioannou; Martin B Delatycki
Journal:  Neurogenetics       Date:  2003-12-19       Impact factor: 2.660

Review 3.  Neuronal degeneration and mitochondrial dysfunction.

Authors:  Eric A Schon; Giovanni Manfredi
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

4.  Defects in mitochondrial axonal transport and membrane potential without increased reactive oxygen species production in a Drosophila model of Friedreich ataxia.

Authors:  Yujiro Shidara; Peter J Hollenbeck
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

5.  Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia.

Authors:  Mariana Igoillo-Esteve; Ana F Oliveira; Cristina Cosentino; Federica Fantuzzi; Céline Demarez; Sanna Toivonen; Amélie Hu; Satyan Chintawar; Miguel Lopes; Nathalie Pachera; Ying Cai; Baroj Abdulkarim; Myriam Rai; Lorella Marselli; Piero Marchetti; Mohammad Tariq; Jean-Christophe Jonas; Marina Boscolo; Massimo Pandolfo; Décio L Eizirik; Miriam Cnop
Journal:  JCI Insight       Date:  2020-01-30

6.  PEP-1-frataxin significantly increases cell proliferation and neuroblast differentiation by reducing lipid peroxidation in the mouse dentate gyrus.

Authors:  Woosuk Kim; Dae Won Kim; Bich Na Shin; Dae Young Yoo; Sung Min Nam; Mi Jin Kim; Jung Hoon Choi; Yeo Sung Yoon; Moo-Ho Won; Soo Young Choi; In Koo Hwang
Journal:  Neurochem Res       Date:  2011-09-01       Impact factor: 3.996

7.  Iron-binding activity in yeast frataxin entails a trade off with stability in the alpha1/beta1 acidic ridge region.

Authors:  Ana R Correia; Tao Wang; Elizabeth A Craig; Cláudio M Gomes
Journal:  Biochem J       Date:  2010-02-09       Impact factor: 3.857

Review 8.  Pharmacological treatments for Friedreich ataxia.

Authors:  Mary Kearney; Richard W Orrell; Michael Fahey; Ruth Brassington; Massimo Pandolfo
Journal:  Cochrane Database Syst Rev       Date:  2016-08-30

9.  Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of Idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich Ataxia.

Authors:  Matthias L Jauslin; Silvia Vertuani; Elisa Durini; Lisa Buzzoni; Nunzia Ciliberti; Sara Verdecchia; Paola Palozza; Thomas Meier; Stefano Manfredini
Journal:  Mol Cell Biochem       Date:  2007-05-03       Impact factor: 3.396

Review 10.  Therapeutic strategies in Friedreich's ataxia.

Authors:  Timothy E Richardson; Heather N Kelly; Amanda E Yu; James W Simpkins
Journal:  Brain Res       Date:  2013-04-13       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.